Humanetics Issued Patent For Alzheimer’s Treatment

By Joseph Mandour on July 2, 2012

molecule-computer1-200x133 Orange County – After years of research and development with Mount Sinai School of Medicine (MSSM), Humanetics Corporation announced today that it has been granted a patent for its Alzheimer prevention and treatment compound, NIC5-15. The newly patented product was developed to provide a safe, effective and accessible method for treatment and prevention of Alzheimer’s disease.

The patent registration materials list NIC5-15 as comprised of methods for treating Alzheimer’s disease and related disorders, as well as methodologies for creating healthy nervous systems. Both MSSM and Humanetics are particularly excited about the product, which is currently undergoing clinical trials in the New York area. Alzheimer sufferers are hopeful, as the treatment has shown positive strides in preventing the formation of beta-amyloid plaques in pre-clinical and animal testing. The formation of these plaques is widely believed to be one of the leading causes of Alzheimer’s disease.

In light of fact that the life span for both men and women in the United States is longer than it’s ever been, an aging population is now at an increased risk for many dangerous and debilitating conditions. Cancers, heart disease and dementia are on the rise and have crippled many Americans. Almost unheard of twenty years ago, Alzheimer’s disease has come to the forefront of the medical community, as it continues to devastate a huge portion of the population. Currently, it is reported that as many as 4.5 million Americans suffer from the damaging effects of Alzheimer’s disease. Millions more are thought to be affected worldwide. It is estimated that in the United States alone, over 2 billion dollars is spent annually on research and treatment to alleviate the suffering caused by this disease. At this point, there are no significantly effective treatments for preventing or reducing the build up of amyloid plaques. However, Humanetics believes that patent 8,193,250 will fulfill the urgent need for safe and effective treatment of Alzheimer’s disease.

Humanetics is based in Minneapolis, Minnesota and is currently in clinical trials with compositions for medical radiation countermeasures, Alzheimer’s disease, Post Traumatic Stress Disorders and Obesity. The privately held company is committed to finding cures for diseases and promoting a means to create a more healthful society. The patents for its latest treatments are concurrently in the patent registration process.

Related Articles:

Posted in: Patent Registration